System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Jean-Yves Blay is an expert in Oncology at Centre Léon Bérard (France). As of October 2026, ScienceLeadR ranks Jean-Yves Blay in the top 1% of experts worldwide for Sarcoma, Chondrosarcoma and Bone Neoplasms. Jean-Yves Blay has authored 1,911 publications, the most recent in 2026, and is an investigator in 112 clinical trials, 16 of them ongoing. SLR score: 9,266 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Jean-Yves Blay Centre Léon Bérard France
9 266 ScienceLeadR Reputation 9266

Unlock

Register Login
Network Map

Oncology

Subspecialties: Surgery - Public Health - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1988 - 2026
Source: PubMed

UniCancer Group

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1911

Citations

Citations: 95 160 1st author: 174 Last author: 371 Unique author: 46

Main journals

J Clin Oncol 321
Ann Oncol 296
Eur J Cancer 124
Bull Cancer 89
Cancer Res 63

Best Journals

Ann Oncol 96
J Clin Oncol 80
Lancet Oncol 39

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Head & Neck and Shoulder Desmoid-Type Fibromatosis: Presentation and Natural History of These Ultra-Rare Locations.
PMID 42905937 — fibromatosis, aggressive, natural history, pain, neoplasms, history		Cancer Med20260
Activity of Low Dose Nivolumab in Patients With Advanced Squamous Cell Carcinomas and Other Cancers.
PMID 42899502 — cells, carcinoma, squamous cell, neoplasms, sarcoma, nivolumab, therapeutics		Int J Cancer20260
Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial.
PMID 42898002 — cells, safety, giant cell tumors, giant cell tumor of tendon sheath, neoplasms, giant cells, response evaluation criteria in solid tumors, therapeutics		Oncologist20260
The 2026 World Health Organization Classification of Tumors of Soft Tissue and Bone: 6th Edition.
PMID 42839882 — surgical oncology, cells, genetics, neoplasms, classification, sarcoma, tissues		Am J Surg Pathol20260
Tools for providing information to patients about high-tech medical resources for treatment of cancer.
PMID 42825514 — physics, neoplasms, solutions, work, diagnosis, therapeutics, medical oncology		Acta Oncol20260

Clinical Studies 112

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 28 Study Chair: 3 Sub-Investigator: 1

By phase:

Phase 2 46
Phase 3 29
N/A 18
Phase 1/Phase 2 9
Phase 1 7
Phase 2/Phase 3 2
Phase 4 1

By status:

Completed 64
Recruiting 22
Active not recruiting 17
Unknown 5
Terminated 3
Suspended 1

By type:

Interventional 103
Observational 9

By Monocentric/Multicentric:

monocentric 10
multicentric2to4 6
multicentric5to9 23
multicentricup10 73

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

16 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
First in Human Study of ADCE D01 in Soft Tissue Sarcoma (ADCElerate 1)
2024-516900-41-00 — safety, dna topoisomerases, type i, sarcoma, topoisomerase i inhibitors, tissues, pharmacokinetics		Phase 1/Phase 2Recruiting2025
Public Title Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First line Treatment in Participants with Metastatic Leiomyosarcoma
2022-502975-45-00 — leiomyosarcoma, doxorubicin, therapeutics		Phase 3Active not recruiting2023
A study to test long term treatment with brigimadlin in people with solid tumours who took part in a previous study with this medicine
2024-514177-21-00 — safety, therapeutics		Phase 2Recruiting2024
First in Human Study of ADCE D01 in Soft Tissue Sarcoma
NCT06797999 — safety, plasminogen, pharmaceutical preparations, plasminogen activators, dna topoisomerases, type i, sarcoma, topoisomerase i inhibitors, immunoconjugates, peptide hydrolases, urokinase-type plasminogen activator, receptors, urokinase plasminogen activator, therapeutics, tissues, pharmacokinetics		Phase 1/Phase 2Recruiting2025
Genetic Newborn Screening for Rare Diseases Within the Screen4Care Project
NCT06549218 — digital technology, whole genome sequencing, infant, newborn, rare diseases, neonatal screening, genome, signs and symptoms, diagnosis, genetic diseases, inborn		N/ARecruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS